[Federal Register Volume 65, Number 20 (Monday, January 31, 2000)]
[Unknown Section]
[Pages 4613-4614]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-1919]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee on Immunization Practices: Meeting

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following committee meeting:

    Name: Advisory Committee on Immunization Practices (ACIP).
    Times and Dates: 8:30 a.m.-6 p.m., February 16, 2000. 8 a.m.-5 
p.m., February 17, 2000.
    Place: Atlanta Marriott Century Center, 2000 Century Boulevard, 
NE., Atlanta, Georgia 30345-3377.
    Status: Open to the public, limited only by the space available.
    Purpose: The Committee is charged with advising the Director, 
CDC, on the appropriate uses of immunizing agents. In addition, 
under 42 U.S.C. Sec. 1396s, the Committee is mandated to establish 
and periodically review and, as appropriate, revise the list of 
vaccines for administration to vaccine-eligible children through the 
Vaccines for Children (VFC) program, along with schedules regarding 
the appropriate periodicity, dosage, and contraindications 
applicable to the vaccines.
    Matters To Be Discussed: The agenda will include a discussion on 
the revision of the ACIP recommendations for the pneumococcal 
conjugate vaccine; cost benefit analysis of the pneumococcal 
conjugate vaccine; update on the revision of the general 
recommendations; update on the adult immunization recommendations; 
update on the standing orders for adult immunization, adverse events 
after use of yellow fever vaccine; prevention of pneumococcal 
disease and vaccination in persons 50-64 years of age; use of DTaP 
as the fifth dose following four doses of DTaP; 2000-2001 control 
and prevention of influenza recommendations; update of 1999-2000 
influenza season and vaccine strain selection process; lyme disease 
vaccine update: trials in children, alternate dosing, boosters, 
VAERS data; effect of changes in hepatitis B immunization 
recommendations due to concerns about thimerosal; 2-dose adolescent 
hepatitis B vaccination; Vaccines for Children vote on FDA approved 
schedule for 2-dose adolescent hepatitis B vaccination, inactivated 
polio virus vaccine, pneumococcal vaccine, and rotavirus vaccine; 
high-speed needle-free jet injectors and mass vaccination for 
pandemic influenza or bioterrorism; update on the bioterrorism and 
anthrax work group; an update from the Food and Drug Administration; 
update from the National Center for Infectious Diseases; update from 
the National Immunization Program; update from the Vaccine Injury 
Compensation Program; update from the National Vaccine Program; 
review of immunogenicity of Pentacel and update on the 
Infanrix vaccine. Other matters of relevance among the 
committee's objectives may be discussed.
    Agenda items are subject to change as priorities dictate.

CONTACT PERSON FOR MORE INFORMATION: Gloria A. Kovach, Program Analyst, 
Epidemiology and Surveillance Division, National Immunization Program, 
CDC, 1600 Clifton Road, NE., m/s E61, Atlanta, Georgia 30333. Telephone 
404/639-8096.
    The Director, Management Analysis and Services office has been 
delegated the authority to sign Federal Register

[[Page 4614]]

notices pertaining to announcements of meetings and other committee 
management activities for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

    Dated: January 20, 2000.
Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention (CDC).
[FR Doc. 00-1919 Filed 1-28-00; 8:45 am]
BILLING CODE 4163-18-P